British mother revealed to have died of food poisoning in Turkey
A British mother who tragically died on holiday in Turkey was found to have had lost her life due to food poisoning.
Beth Martin, 28, from Portsmouth, became 'delirious' on the first day of the trip and was placed in critical care.
She had been on holiday with her husband Luke and two children, aged eight and five but died around a day after she was taken into hospital on April 28, it was reported by the Daily Mail.
Her family claimed they were not informed about the serious nature of her condition and Turkish authorities had accused Luke of 'poisoning' his wife.
It emerged following a UK autopsy that Mrs Martin's heart had been removed following her death although no permission had been sought from her family, according to a family fundraiser.
A new report has indicated that the mother had died due to food poisoning, according to local media outlet Sozcu and found no evidence she died from 'traumatic effects'.
Findings, released by the Forensic Medicine Institution, said: 'It has been concluded that Martin's death occurred as a result of food poisoning and its complications.'
It reportedly added the full examination of Beth's heart had been completed.
Her devastated husband Luke previously said he has suffered the 'deepest level of trauma' following his wife's death and added that telling his children they would never see their mother again 'broke him'.
'Two weeks ago me, my wife and two kids set out for a family holiday to Turkey. Only three of us made it back,' Luke wrote on social media on May 11.
'I lost my wife, my children lost their mum, we lost the biggest piece of the puzzle that was our family.
'It has been the worst and most traumatic week of my entire life, and to top it off. I had to break the news to my babies that their mum isn't coming home, it broke me.'
Mrs Martin started to feel unwell after the family touched down at the airport in Turkey on Sunday, April 27, leading her husband to call for an ambulance the following day.
She was taken to a 'destitute' hospital where she was quickly transferred into intensive care.
It was claimed on a GoFundMe page, Mr Martin was 'banned' from seeing his wife and had not been updated on her condition as she was being cared for in hospital.
Doctors raised concerns at the time about Mrs Martin's heart but she died the day after being taken into hospital.
The family alleged they were made to carry her body in a bag throughout the hospital and claimed they were told they would have to wait more than a fortnight to repatriate her body so Luke 'paid thousands' for her to be flown home alongside him on the same flight.
Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
EULAR, ERS Issue First Guideline for Managing CTD-ILD
BARCELONA, Spain — All patients with systemic sclerosis (SSc) and mixed connective tissue disease (MCTD) should be screened for interstitial lung disease (ILD), according to new guidelines presented at the European Alliance of Associations for Rheumatology (EULAR) 2025 Annual Meeting. The guidelines are a collaboration between EULAR and the European Respiratory Society (ERS) to provide comprehensive, disease-specific recommendations for the screening, diagnosis, and management of ILD in patients with connective tissue diseases (CTDs), including SSc, MCTD, rheumatoid arthritis (RA), idiopathic inflammatory myopathies (IIM), and Sjögren's disease (SjD). "These are the first recommendations [for ILD] that have been developed by rheumatologists and pulmonologists together in Europe," said Bernhard Hellmich, MD, of the University of Tübingen, Germany. He was not involved with the work but moderated the session during which the recommendations were presented. The ERS has published guidelines solely focusing on therapies for ILD, but "the meaningful impact [of these new guidelines] is that it is interdisciplinary work," he said. Screening for ILD The guidelines strongly recommend systematic screening for ILD with high-resolution computed tomography (HRCT) in all patients with SSc and MCTD, regardless of risk factors. This recommendation also applies to patients with IIM, except those with inclusion body myositis. Patients with RA, SjD, and other CTDs should first be assessed for disease-specific risk factors. Patients with identified risk factors should be screened with HRCT. Although some previous recommendations supported screening in SSc, "now the big news is that we should also screen patients with RA who have risk factors," Hellmich said. "We have not done this before, so this will certainly identify more patients who are eligible for therapy and may improve [outcomes] down the line." The guidelines do not include any recommendations on screening frequency because of a lack of evidence, explained Anna-Maria Hoffmann-Vold, MD, PhD, of Oslo University Hospital, Norway, who presented the guidelines. She advised that providers use the same approach as that used at the timepoint of diagnosis and assess for any new risk factors for ILD progression. Any patient with additional red flags such as sustained joint disease in RA should be re-screened, she said. "Of course, in any case of suspicion, re-screen the patient," she continued. The guidelines strongly recommend against replacing HRCT with pulmonary function tests or lung ultrasound for screening for ILD; however, forced vital capacity and diffusing capacity of the lungs for carbon monoxide can be included in case of symptoms or CT abnormalities. Monitoring After Diagnosis The guidelines do have time recommendations for monitoring ILD progression after diagnosis. The recommendations are disease-specific and stratified by risk of ILD progression. Clinicians can assess risk for ILD progression in the following year by looking at prior lung function tests, HRCT results, the 6-minute walking test, and risk factors for poor outcomes in ILD, which include disease-specific circulating markers, higher disease activity, and HRCT pattern and extent. Based on these factors, clinicians can categorize patients as higher or lower risk, Hoffmann-Vold said. "Next, you look at the disease duration of the patient — whether you have a shorter disease duration or longer disease duration in the high-risk group and the low-risk group," she explained during her presentation. "Based on this, you apply the monitoring tools we have identified." Although some time recommendations vary by disease, for high-risk patients with any CTD, lung function tests should be performed every 3-6 months in the first years of disease and every 6-12 months thereafter. For lower-risk patients, perform lung tests every 6-12 months in the first years of disease and annually thereafter. Treatment Recommendations The new treatment recommendations "not only list which treatment options are available for every disease but also give hints [about] which patient might be the right one for a certain medication," Hoffmann-Vold said. The group strongly recommends that patients with SSc-ILD with early diffuse SSc and signs of inflammation should be treated with tocilizumab and that patients with any IIM-ILD should be treated with immunosuppressive treatment, which can include glucocorticoids, calcineurin inhibitors, rituximab, mycophenolate, or azathioprine. Other recommendations are conditional, largely because of limited patient populations and a small number of randomized controlled trials. SSc-ILD, RA-ILD, and IIM-ILD all have individual treatment algorithms. This comprehensive guideline will "certainly help to get patients earlier into treatment," Hellmich added. "Some of these therapies [currently] are more or less off-label," he said. But if they are included in EULAR guidelines, "people are more likely to use them in clinical practice and to improve prognosis." The full guidelines will be published next month in Annals of the Rheumatic Diseases and European Respiratory Journal .
Medscape
4 hours ago
- Medscape
MRD: A Shared Compass for Patients, Clinicians, and Regulators
MILAN — The landscape of hematologic malignancies is shifting rapidly, in part due to the evolving significance of measurable (formerly "minimal") residual disease (MRD). Once confined to the realm of research, MRD is emerging as a critical tool for clinical and regulatory decision-making. In conditions such as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and multiple myeloma (MM), MRD has become more than a marker of extent of disease burden; it now informs prognosis, therapeutic response, and access to novel treatments. "MRD is not a new concept; it has been studied for years", Jesus San Miguel Izquierdo, MD, PhD, director of clinical and translational medicine at the University of Navarra, Pamplona, Spain, told Medscape Medical News . Thanks to technological advances, unprecedented sensitivity in detecting residual cancer cells following treatment, in other words MRD, has been achieved. "We are capable of identifying a single tumor cell among a million," said San Miguel Izquierdo, who was awarded the 2025 EHA Lifetime Achievement Award for his lifelong work in MM. At a multidisciplinary session here at the European Hematology Association (EHA) 2025 Annual Meeting in Milan, representatives of patient organizations, clinicians, and regulatory bodies offered insights into the expanding role of MRD. Although its utility as an indicator of treatment response is widely recognized, debates remain over standardization, regulatory implications, and its intersection with patient experience and access. The Patient Voice: MRD as a Tool of Hope and Anxiety Anne-Pierre Pickaert, a survivor of ALL and patient advocate, described MRD in profoundly personal terms. For many patients, MRD is both a beacon and a burden. "It's like a needle in a haystack," she explained, noting that the absence of detectable cancer cells does not always equate to the absence of disease, and that uncertainty can be emotionally taxing. The terminology shift from "minimal" to "measurable" residual disease may have technical sense, but it can be unsettling for patients. "Minimal" is often interpreted as benign or reassuring, whereas "measurable" conveys clinical precision but may also amplify anxiety. Conversely, "minimal" can offer false reassurance, underestimating actual risk. There are also disparities in how MRD is communicated and understood across different hematologic diseases. For patients with ALL or AML, MRD status can dictate eligibility for transplants, trials, or access to novel therapies. In contrast, patients with chronic lymphocytic leukemia or lymphoma may be less familiar with the concept, reflecting its inconsistent use in routine care. Advocacy networks face challenges in delivering cohesive education across this diverse landscape. Pickaert also used the term "MRD-xiety," likening it to the "scanxiety" experienced by patients with solid tumors awaiting imaging results. As MRD often determines treatment direction, it carries substantial emotional weight. Yet most patients remain unaware of the regulatory frameworks that shape access to MRD-guided interventions. "We just want access," she said, be it through compassionate use, early access programs, or full reimbursement. Clinician Perspective: A Shift in Therapeutic Strategy Nicola Gökbuget, MD, head of the study center, department of hematology/oncology, University Cancer Center, Frankfurt, Germany, highlighted how MRD is transforming clinical strategy. Presenting an ALL case, she emphasized the paradigm shift from hematologic to molecular decision-making. "Historically, we acted on clinical relapse. Today, persistent or re-emerging MRD — as a molecular failure — can prompt therapeutic changes." This proactive model is influencing clinical trial designs and enabling more personalized approaches, such as targeting residual disease before transplant. In contrast, classical strategies relied on hematologic response and salvage therapy after hematologic progression. Still, the clinical utility of MRD depends on standardization. Clinicians need consensus definitions for response categories — complete molecular remission, intermediate response, molecular failure — as well as harmonized testing modalities and timepoints. Gökbuget stressed that the value of MRD risks being undermined without unified standards. Coordinated efforts from academic groups and industry partners will be essential. The Regulatory View: Is Surrogacy the Right Goal? Pierre Démolis, MD, PhD, chair of the Oncology Working Party and co-chair of the Scientific Advice Working Party at the European Medicines Agency, discussed the nuanced regulatory stance on MRD. Although MRD is a powerful indicator of response, it is not yet a validated surrogate endpoint. Surrogacy, in regulatory terms, requires consistent, reproducible correlation with overall survival across various contexts; something MRD has not fully achieved. Still, Démolis advocates for MRD as a "response trigger" in adaptive designs, transplant decisions, and early treatment assessments. "Let's stop pretending surrogacy is required to make MRD useful," he said. "It's like objective response rate or complete hematologic response; we've used such endpoints for decades." He clarified the distinction between activity and efficacy: activity refers to pharmacodynamic effects (eg, tumor shrinkage, MRD negativity), while efficacy denotes clinical benefit (eg, overall survival, progression-free survival). Activity-based endpoints such as MRD are already used in single-arm trials, particularly when randomized data are impractical. However, MRD should not replace overall survival as the final endpoint. "It can be used in conditional settings, provided final efficacy outcomes confirm its relevance," he added. Survey Shows Divergence in Attitudes Anna Smit, a PhD candidate at Erasmus MC Cancer Institute in Rotterdam, the Netherlands, presented preliminary findings from a joint EHA-International Myeloma Society survey on the role of MRD in MM trials. Among 389 healthcare professionals and 40 regulators surveyed, most supported MRD negativity as a primary endpoint, regardless of transplant eligibility. Nearly all respondents emphasized the need for global standardization. Yet variation in techniques and sensitivities remains a major barrier. Smit noted that in April 2024, the Oncologic Drugs Advisory Committee of the US Food and Drug Administration unanimously supported MRD-negative complete response as an endpoint to justify accelerated approval in MM. Europe, however, has not yet agreed to this and continues to monitor the field. Démolis confirmed ongoing global regulatory discussions on different topics, including MRD, highlighting monthly exchanges among agencies to share and possibly align perspectives. Patient-Centered Medicine Remains Paramount Quality of life (QoL) was also discussed during the session as another important aspect of the patient-centered approach to hematologic malignancies. For Pickaert, QoL is a non-negotiable endpoint: "Patients want survival, but not at any cost." Démolis echoed this view: "If you prolong life by a month but destroy QoL, is that meaningful?" Gökbuget acknowledged the practical difficulties of collecting QoL data, especially in acutely ill populations, but emphasized that such hurdles are not insurmountable. "Even when patients are unwell, someone can help complete the questionnaire," Pickaert said. Integrating QoL into MRD-based strategies could ensure that treatments extend not just life but also well-being. "As regulators, we must prioritize QoL in our decisions," Démolis said. San Miguel Izquierdo reinforced this message in a comment to Medscape Medical News . "Looking at MRD allows for early intervention," he said, implicitly linking early intervention to better QoL. Although some clinicians worry about overtreatment, the risk of undertreatment is often far greater. "By ignoring MRD, we risk undertreating 90% of patients and overtreating 10%," he concluded. Pickaert, Smit, and Démolis have reported no relevant financial relationships. Gökbuget has reported advisory board participation for and speaker honoraria and travel support from Amgen, AstraZeneca, Autolus, Celgene, Clinigen, Gilead, Incyte, Jazz Pharmaceuticals, Novartis, Pfizer, Sanofi, and Servier; and institutional research support from Amgen, Clinigen, Incyte, Jazz Pharmaceuticals, Novartis, and Servier. San Miguel Izquierdo has declared participation on advisory boards and consulting services, on behalf of his institution, for AbbVie, Amgen, BMS, Celgene, GSK, Haemalogix, Janssen-Cilag, Karyopharm, MSD, Novartis, Pfizer, Takeda, Regeneron, Roche, Sanofi, Secura Bio, and Gilead-Kite.
Yahoo
4 hours ago
- Yahoo
5 Foods to Buy Every Week to Help Reduce Your Stroke Risk, Recommended by Dietitians
Reviewed by Dietitian Kelly Plowe, M.S., RDEating a Mediterranean-style diet focused on whole foods can reduce your risk of stroke. Experts share their top five favorite foods, including salmon, chickpeas and spinach, to keep your stroke risk low. Staying active, getting regular checkups and limiting alcohol can also brain is arguably your body's most important organ, serving as the command center for thought, memory, emotion and innumerable everyday functions. For obvious reasons, protecting it from the debilitating effects of stroke is critical. Fortunately, you can shore up your brain's vascular defenses with what you put in your shopping cart—and ultimately on your plate. 'Eating well plays a supportive role in reducing stroke risk and supporting recovery after a stroke,' says Vanessa King, M.S., RDN. 'A heart-healthy, Mediterranean-style eating plan rich in olive oil, whole grains, fruits, vegetables and legumes has been shown to cut stroke risk by 40% for high-risk individuals.' An additional study adds to this, finding that those with the highest-quality diets (as determined by the Alternative Healthy Eating Index) had a 40% lower risk of stroke compared to those with the lowest-quality diets, regardless of other lifestyle factors. Dietitians share five delicious foods that fall under this dietary umbrella, helping keep your stroke risk low. Seafood and stroke reduction go hand in hand. Research shows that eating fish lowers your risk of stroke. This is especially true if the fish is a source of omega-3 fatty acids, like salmon, tuna and mackerel. If you're looking to boost your seafood intake, salmon is a tasty, high-protein place to start. 'Three ounces of cooked salmon is a great source of vitamins B6 and B12, providing 23% of the Daily Value of B6 and over 100% of the Daily Value of B12,' says King. These B vitamins may lower total blood homocysteine concentrations—a key risk factor for stroke. King suggests enjoying the pink fish as a protein topper for salads like Salad Niçoise or making a simple baked version. For stroke prevention, there's no need to ditch your morning coffee, says Amy Brownstein, M.S., RDN. The reason for java's beneficial effects in the brain? 'Besides its caffeine content, coffee is a significant source of polyphenols like chlorogenic acid, which may contribute to lower blood pressure levels,' shares Brownstein. As part of your coffee routine, Brownstein recommends limiting sweeteners. Increasing evidence shows that added sugars can contribute to stroke risk. Check out these healthy coffee drinks for inspiration. You probably know spinach is packed with nutrients, but did you know those nutrients promote blood flow in your brain? 'A half-cup of cooked spinach is a great source of folate and a good source of magnesium,' says King. One study found that high dietary folate intake was linked to a 17% reduction in incidence of stroke. Another study revealed that those with higher magnesium intakes (18.5 milligrams or more per 100 calories a day) had a 40% reduced risk of stroke compared to those on the lower end of magnesium intake (12 mg per 100 calories a day). For reference, on a 2,000-calorie diet, this would equate to 370 mg a day on the higher end and 240 mg on the lower end. Go green with recipes that serve spinach hot or cold. 'It can be cooked in olive oil and topped with pumpkin seeds and raisins in a Spanish style,' suggests King. Or, for a warmer-weather preparation, a strawberry-balsamic spinach salad might hit the spot. Small-but-mighty chickpeas are another nutrient-dense choice packed with stroke-fighting vitamins. According to King, a cup of these versatile beans adds 10% of the Daily Value of homocysteine-lowering vitamin B6. And since they come conveniently precooked, it's easy to crack open a can to upgrade nutrition in your meals. 'They serve as a fiber-rich protein source for stews, salads, curries and snacks,' says King. It's time to put misconceptions about soy foods to rest. Choices like tofu, tempeh and edamame are all top-notch proteins for both your brain and your heart. 'Soy proteins lower blood pressure,' says Brownstein. 'They're naturally low in fat, and compounds like phytoestrogens and isoflavones positively influence blood pressure by potentially relaxing blood vessels.' You don't have to completely replace meat with soy to enjoy these benefits, either. Brownstein suggests starting with a meatless Monday—replace one meat-based meal with a soy-based food. (These beefless tacos are an easy place to start!) Choosing cardiovascular-friendly foods is, of course, only one piece of the stroke prevention puzzle. Reducing your risk involves multiple lifestyle factors. In your efforts to stay stroke-free, try incorporating the following: Get active: 'Participate in regular physical activity to help maintain a healthy weight and cholesterol and blood pressure levels,' Brownstein advises. The American Heart Association recommends 150 minutes of moderate-intensity aerobic exercise per week. Quit smoking. If you're a smoker, ditching this habit is one of the most effective ways to decrease your risk of stroke. . Alcohol is known for raising both blood pressure and cholesterol. Stick to the recommended intake of two alcoholic drinks or fewer per day for men and one drink or fewer for women. Get regular checkups. 'Routine blood work and medical evaluations help you stay on top of your health, enabling you to make lifestyle changes before complications arise,' says Brownstein. She recommends regular checks on blood sugar, cholesterol and blood pressure. Filling your grocery cart with stroke-prevention foods doesn't have to involve anything fancy. Plenty of everyday items can play a role in keeping a healthy blood flow in your brain. Try focusing on nutrient-dense whole foods that are lower in sodium and that provide vitamins and minerals like folic acid, vitamin B12, vitamin B6 and magnesium. Every bite adds up! 'Even small shifts in the kitchen can make a big impact on stroke prevention,' says King. Read the original article on EATINGWELL
